Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Oct 15, 2024; 15(10): 2036-2040
Published online Oct 15, 2024. doi: 10.4239/wjd.v15.i10.2036
Surgical or medical treatment of obesity-associated type 2 diabetes-an increasing clinical conundrum
Ryan J Jalleh, Karen L Jones, Md Shahidul Islam, Lu Cai, Michael Horowitz
Ryan J Jalleh, Karen L Jones, Michael Horowitz, Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide; and Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide 5000, South Australia, Australia
Md Shahidul Islam, Department of Biochemistry, School of Life Sciences, University of KwaZulu-Natal, Durban 4000, KwaZulu-Natal, South Africa
Lu Cai, Pediatric Research Institute, Departments of Pediatrics, Radiation Oncology, Phar-macology and Toxicology, University of Louisville, Wendy Novak Diabetes Institute, Norton Children’s Hospital, Louisville, KY 40202, United States
Author contributions: Jalleh RJ wrote the original draft; Jones KL, Islam MS, Cai L reviewed and edited it; Horowitz M was the senior author and provided supervision and validation of the writing.
Conflict-of-interest statement: Jones KL has previously received research funding from Sanofi-Aventis and AstraZeneca; participated on an advisory board for Glyscend Therapeutics (without receipt of payment); and declares stock options, but does not own any stock, in Glyscend Therapeutics. Horowitz M declares stocks in Mirum Pharmaceuticals, a company that owns Livmarli (maralixibat), which is approved in the United States and Europe for the treatment of cholestatic pruritus in Alagille syndrome (a genetic liver disorder). Mirum Pharmaceuticals has work underway related to rare liver diseases, but not diabetes or obesity. Horowitz M declares stock options, but does not own any stock, in Glyscend Therapeutics; and is a member of the scientific and clinical advisory board for Glyscend Therapeutics. All other authors declare no competing interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Michael Horowitz, DSc, FRACP, MBBS, PhD, Professor, Adelaide Medical School, University of Adelaide, Level 5, AHMS Corner North Tce and George St, Adelaide 5000, Australia. michael.horowitz@adelaide.edu.au
Received: August 14, 2024
Revised: September 9, 2024
Accepted: September 14, 2024
Published online: October 15, 2024
Processing time: 43 Days and 6.9 Hours
Core Tip

Core Tip: Glucagon-like peptide-1 receptor agonist-based therapy should be considered for the remission of type 2 diabetes and weight loss as an alternative to bariatric surgery.